Mild cognitive impairment: To treat or not to treat
Tóm tắt
Mild cognitive impairment (MCI) refers to memory deficits in excess of normal aging, but not sufficient for the diagnosis of Alzheimer’s disease (AD). In general, patients with MCI are not disabled and have no other obvious cognitive deficits other than memory. Many studies have shown that patients with MCI are more likely to progress to AD than age-matched controls. Drug therapy to prevent or delay deterioration in patients with MCI has been tested only very recently. The results of three clinical trials are discussed. One of two trials with donepizil suggests that donepizil may delay onset of AD, but the effect is modest and the side effects are problematic. Galantamine appeared to be associated with excess deaths, and vitamin E was not effective. No medications are currently indicated for the prevention of dementia in patients with MCI.
Tài liệu tham khảo
Kral VA: Senescent forgetfulness: benign and malignant. Can Med Assoc J 1962, 86:257–260.
Crook T, Bartus RT, Ferris SH, et al.: Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change—report of a National Institute of Mental Health work group. Dev Neuropsychol 1986, 2:261–276.
Petersen RC, Smith GE, Waring SC, et al.: Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol 1999, 56:303–308.
Petersen RC, Stevens JC, Ganguli M, et al.: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133–1142. Important reference.
Winblad B, Palmer K, Kivipelto M, et al.: Mild cognitive impairment—beyond controversies, towards a consensus: report of the International Working Group on mild cognitive impairment. J Intern Med 2004, 256:240–246.
Morris JC, Storandt M, Miller JP, et al.: Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 2001, 58:397–405.
Bozoki A, Giordani B, Heidebrink JL, et al.: Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001, 58:411–416.
Albert MS, Moss MB, Tanzi R, Jones K: Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001, 7:631–639.
Tierney MC, Szalai JP, Snow WG, et al.: A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996, 46:149–154.
Okamura N, Arai H, Maruyama M, et al.: Combined analysis of CSF tau levels and iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer’s disease. Am J Psychiatry 2002, 159:474–476.
Jack CR, Petersen RC, Xu YC, et al.: Prediction of AD with MRIbased hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397–1403.
Small SA, Perera GM, DelaPaz R, et al.: Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer’s disease. Ann Neurol 1999, 45:466–472.
Dickerson BC, Salat DH, Bates JF, et al.: Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004, 56:27–35.
Dubois B, Albert ML: Amnestic MCI or prodromal Alzheimer’s disease? Lancet Neurol 2004, 3:246–248.
Cummings JL: Alzheimer’s disease. N Engl J Med 2004, 351:56–67. Important reference.
Salloway S, Ferris S, Kluger A, et al.: Efficacy of donepizil in mild cognitive impairment. A randomized placebocontrolled trial. Neurology 2004, 63:651–657.
Petersen RC, Thomas RG, Grundman M, et al.: Vitamin E and donepizil for the treatment of mild cognitive impairment. New Engl J Med 2005, 352:2379–2388. Important reference.
Sano M, Ernesto C, Thomas RG, et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997, 336:1216–1222.
Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Int Med 2005, 142:37–46.